CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited...
Shionogi
BioVersys Partners with Shionogi to Advance BV500 for Non-Tuberculous Mycobacterial Infections
Swiss biopharma BioVersys AG (SWX: BIOV) announced a research and exclusive license option agreement with...
Shionogi Partners with Link Medical for Cefiderocol Development in Australia and New Zealand
Japan-based Shionogi Co., Ltd. has entered into an exclusive licensing agreement with Link Medical Products...
Shionogi Submits Rolling NDA for Ensitrelvir in US for COVID-19 Prophylaxis
Shionogi announced on April 1, 2025, the initiation of a rolling New Drug Application (NDA)...
Kelun Pharmaceutical’s Generic Mulpleta Gains NMPA Approval in China
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that it has received marketing...
Sino Biopharmaceutical’s Chia Tai Tianqing Secures Exclusive Promotion Rights for Naldemedine in China
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced an exclusive market promotion agreement between its...
Vocabria Receives Positive CHMP Opinion for HIV Treatment in Adolescents
GSK plc (NYSE: GSK) has announced that ViiV Healthcare, an HIV specialist majority owned by...
Shionogi Files for Chinese Approval of Cefiderocol to Combat Gram-Negative Bacterial Infections
Shionogi Co., Ltd, a prominent Japanese pharmaceutical company, has announced the filing of a New...
Shionogi’s Xofluza Gains Approval in Taiwan for Pediatric Influenza Treatment and Prophylaxis
Shionogi & Co., Ltd, a leading Japanese pharmaceutical company, has announced that it has received...
Shionogi’s Acquisition of Qpex Impacts Brii Biosciences’ Rights to Anti-infective Drugs
Japan’s Shionogi & Co., Ltd (TYO: 4507) announced on June 26, 2023, its planned acquisition...
Sino Biopharmaceutical Secures Rights to Shionogi’s COVID-19 Therapy Ensitrelvir
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia Tai Tianqing...
Shanghai Pharmaceuticals Secures Exclusive Rights for Shionogi’s Ensitrelvir in China
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has announced an import and distribution agreement with Japan-based...
Hansoh Pharma Licenses GHDDI’s GDI-4405 for Global Development in COVID-19
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with the Global...
Shionogi Files NDA for S-217622 COVID-19 Antiviral Drug in China
Japan-based Shionogi & Co., Ltd has submitted a New Drug Application (NDA) to the National...